EN DE
Watch Pharmosa Biopharm Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pharmosa Biopharm Inc. (6875) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Pharmosa Biopharm Inc. stock TWD 7.85, price TWD 25.30, that is 69.0% below the price, quality 29 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

PB Pharmosa Biopharm Inc. logo Thin data Nov 4, 2026

Pharmosa Biopharm Inc.

6875 · TWO
Very expensive, weak quality

Our calculation puts a fair price 69% below what the stock costs today.

Low debt
Revenue last quarter 59% below a year ago.
Fair value 7.85 TWD · Strongly overvalued
Quality 29/100
Weak Growth (revenue YoY −59.9 %/yr in TWD)
Negative free cash flow
Trails peers (1/8)
Narrow moat 8/100 · thin data
Thin data
Watch Pharmosa Biopharm Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

134.97 TWD 25.30 TWD Fair Value 7.85 TWD Feb 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

56‑month range 25.30 TWD – 134.97 TWD · fair‑value band 5.18 TWD – 9.81 TWD · the 25.30 TWD price screens above the 7.85 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Pharmosa Biopharm in your weekly email

Every Wednesday you see whether Pharmosa Biopharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan.

Show moreShow less

It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease.

The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei, Taiwan.

Stock analysis

Pharmosa Biopharm Inc. (6875) currently trades at 25.30 TWD, while our model-based Fair Value estimate is 7.85 TWD, 69% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the data coverage at low.

Scenario range: 5.18 TWD (bear) to 9.81 TWD (bull), the price of 25.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Pharmosa Biopharm Inc. reported revenue of 67.3M TWD in FY2025 versus 0 TWD in FY2022. Reported net income was −384M TWD in FY2025.

Key figures

Market cap 3.3B TWD (≈ $99.5M) Micro · P/S ratio 65.3 · EPS (TTM) −2.77 TWD · Return on equity −22.8% · Return on assets (EBIT) −21.8% (5-year average) · Operating margin −762% · Revenue (TTM) 53.4M TWD · Revenue growth (YoY) −59.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −69%, 6875 screens richer than that median.

Fair Value models

Bear 5.18 TWD Fair Value 7.85 TWD Bull 9.81 TWD
Price 25.30 TWD · Downside -69.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 5.18 TWD 7.85 TWD 9.81 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 5.18 TWD 7.85 TWD 9.81 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 6
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 74
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6875 screens overvalued: fair value 69% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Pharmosa Biopharm Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −69.0% · Below median
Profitability
Return on assets −22.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) −59.3% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.10× · Pricier than median
P/S (12 months) 61.18× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6875
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6875
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6875
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6875
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6875
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6875
argenx SE ARGX $927.21 $908.40 −2% vs 6875
CSL Limited CSL A$200.77 A$183.04 −9% vs 6875
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6875
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6875

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pharmosa Biopharm Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pharmosa Biopharm Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6875

Frequently asked questions

Is Pharmosa Biopharm Inc. (6875) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 7.85 TWD versus a price of 25.30 TWD, about 69% lower (overvalued).
What is the fair value of 6875?
Our model-based fair value for Pharmosa Biopharm Inc. is 7.85 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 25.30 TWD.
What is the quality score of 6875?
Pharmosa Biopharm Inc. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmosa Biopharm Inc. (6875)?
Our model-based price target is the fair value of 7.85 TWD (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 5.18 TWD, optimistic scenario 9.81 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmosa Biopharm Inc. stock forecast for 2026?
Our models put fair value at 7.85 TWD, about 69% lower versus a price of 25.30 TWD (overvalued). Cautious scenario 5.18 TWD, optimistic scenario 9.81 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Pharmosa Biopharm Inc. (6875)?
Pharmosa Biopharm Inc. reported trailing-twelve-month revenue of about 53.4M TWD (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Pharmosa Biopharm Inc. (6875)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmosa Biopharm Inc. it is 7.85 TWD per share (as of Nov 4, 2026), against a price of 25.30 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Pharmosa Biopharm Inc. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 6875 trades above its calculated fair value: price 25.30 TWD, fair value 7.85 TWD, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6875?
No. The price is what the market pays today (25.30 TWD); the fair value is what the company's own numbers justify (7.85 TWD). For Pharmosa Biopharm Inc. the two are 17.45 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmosa Biopharm Inc. worth?
The market values Pharmosa Biopharm Inc. at about 3.3B TWD (market capitalisation, as of Nov 4, 2026). Per share that is 25.30 TWD; our models calculate a fair value of 7.85 TWD per share.
What do the bullish and bearish scenarios say about 6875?
Our models span a range for Pharmosa Biopharm Inc.: cautious scenario 5.18 TWD, base 7.85 TWD, optimistic 9.81 TWD per share (as of Nov 4, 2026, price 25.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharmosa Biopharm Inc. (6875)?
Balance-sheet figures for Pharmosa Biopharm Inc. (as of Nov 4, 2026): return on equity −22.8%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 6875 from its 52-week high?
Pharmosa Biopharm Inc. trades at 25.30 TWD, about 56% below its 52-week high of 57.30 TWD and at the low of 25.30 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 7.85 TWD is for.
Which stocks are comparable to Pharmosa Biopharm Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmosa Biopharm Inc. stock attractive at the current price?
The data as of Nov 4, 2026: price 25.30 TWD, calculated fair value 7.85 TWD (−69%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6875 calculated?
We run Pharmosa Biopharm Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 7.85 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pharmosa Biopharm Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmosa Biopharm Inc. (6875)?
The closing price on Nov 6, 2026 was 25.30 TWD. Our model-based fair value is 7.85 TWD, about 69% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmosa Biopharm Inc. right now?
The price sits above even our optimistic bull case (9.81 TWD). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (5.18 TWD to 9.81 TWD) leaves room in how you read the outcome.

Key figures of Pharmosa Biopharm Inc.

How large is the market capitalisation of Pharmosa Biopharm Inc. (6875)?
The market capitalisation of Pharmosa Biopharm Inc. is 3.3B TWD (≈ $99.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmosa Biopharm Inc. (6875)?
The price-to-sales ratio of Pharmosa Biopharm Inc. is 65.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharmosa Biopharm Inc. (6875)?
Earnings per share at Pharmosa Biopharm Inc. are −2.77 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pharmosa Biopharm Inc. (6875)?
The return on equity (ROE) of Pharmosa Biopharm Inc. is −22.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmosa Biopharm Inc. (6875)?
On an EBIT basis the return on assets of Pharmosa Biopharm Inc. is −21.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmosa Biopharm Inc. (6875)?
The operating margin of Pharmosa Biopharm Inc. is −762% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmosa Biopharm Inc. (6875)?
Revenue at Pharmosa Biopharm Inc. is growing −59.3% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pharmosa Biopharm Inc. (6875) generate?
The free cash flow of Pharmosa Biopharm Inc. is −477M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Pharmosa Biopharm Inc. (6875) hold?
Pharmosa Biopharm Inc. holds more cash than debt, 830M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Pharmosa Biopharm Inc. in the live analysis

One click puts Pharmosa Biopharm Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.